FDMT

Conviction 92HealthcareScan · Thu, Jun 25, 2026

FDMT$11.50-1.03%

ResistanceSupportVol 14Insider sell

Vol MA14 1.06M

Mar 26Apr 14May 1May 19Jun 8Jun 25

4D Molecular Therapeutics, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.4dmoleculartherapeutics.com ↗

Price11.50

Change-1.03%

Gap+0.47%

Rel volume2.67×

Avg volume1.12M

Avg $ vol11.26M

SMA 209.62

SMA 509.55

SMA 2009.33

Price vs 50+20.48%

Price vs 200+23.31%

MA stackbullish

50/200 cross—

Supertrendup · 9.11

RSI (14)66

MACD hist0.32

MACD crossbull · 5d

Stoch %K / %D82 / 84

ADX (14)22

+DI / −DI38 / 13

RSI divergence—

MACD divergence—

ATR %+7.05%

ADR %8.40%

52w high12.27

52w low3.71

From 52w high-6.28%

Above 52w low+209.97%

New 52w highNo

SqueezeOff

Bollinger width39.58%

%B0.99

Donchian pos82.15%

Donchian high12.18

Donchian low8.37

AVWAP (52w high)9.62

vs AVWAP high+19.51%

AVWAP (52w low)8.51

vs AVWAP low+35.09%

OBV trendUp

Chaikin MF (20)0.09

Today vs 20d2.67×

Avg vol (14d)1.06M

Avg vol (20d)1.12M

Avg $ vol (20d)11.26M

Market cap572.45M

RS 3m (vs SPY)+14.32%

RS 6m (vs SPY)+26.14%

RS line new highYes

Trend template6/8

Technical rank90.8

1 week+22.08%

1 month+32.03%

3 months+16.40%

6 months+32.03%

1 year+187.50%

YTD+57.10%

P/E-4.09

P/B1.27

P/S6.72

P/FCF-5.22

EPS-2.42

Div yield—

ROE-31.01%

ROA-27.32%

Debt/Eq—

Current9.34

EV/EBITDA-3.23

Gross margin—

Net margin-164.43%

Rev growth—

EPS growth12.90%

Price target29.00

Target upside152.17%

Analyst ratingBuy

Institutional103.85%

Ent. value499.96M

Revenue3.05M

Net income-68.76M

Gross profit—

Free cash flow-109.62M

IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ExchangeNasdaq

Shares out52.28M

Employees196

ListedFri, Dec 11, 2020

Free float50.43M

Float %88.3%

Short interest12.19M

Days to cover14.0d

Short volume58.9%

Squeeze score93 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$1.01 vs −$0.97

Last surprise-4.1% miss

Setup gradeA+

Conviction92 / 100

Pattern quality—

Tech rank90.8 / 100

Group rank50 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance11.70

Support8.22

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in FDMT

All disclosures →

No recent disclosed trades by Congress in FDMT. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in FDMT · 8 buys · 2 sells

Insider	Side	Shares	Value	Traded	Filed
Bizily Scott Chief Legal Officer · Stock Option (Right to Buy) · 2026-06-23	Exercise	9.81K	—	2026-06-23	2026-06-25
Bizily Scott Chief Legal Officer · Common Stock · 2026-06-23	Exercise	9.81K	$41K	2026-06-23	2026-06-25
Bizily Scott Chief Legal Officer · Common Stock · 2026-06-23	Sell	9.81K	$118K	2026-06-23	2026-06-25
Chacko Jacob Director · Stock Option (Right to Buy) · 2026-06-17	Grant	50K	—	2026-06-17	2026-06-18
SBLENDORIO GLENN Director · Stock Option (Right to Buy) · 2026-06-17	Grant	50K	—	2026-06-17	2026-06-18
MILLIGAN JOHN F Director · Stock Option (Right to Buy) · 2026-06-17	Grant	75K	—	2026-06-17	2026-06-18
GRAY SUSANNAH Director · Stock Option (Right to Buy) · 2026-06-17	Grant	50K	—	2026-06-17	2026-06-18
Miller-Rich Nancy Director · Stock Option (Right to Buy) · 2026-06-17	Grant	50K	—	2026-06-17	2026-06-18
THEUER CHARLES Director · Stock Option (Right to Buy) · 2026-06-17	Grant	50K	—	2026-06-17	2026-06-18
Tomasello Shawn Director · Stock Option (Right to Buy) · 2026-06-17	Grant	50K	—	2026-06-17	2026-06-18

SEC filings

EDGAR filings in FDMT · 4 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.